Stocks and Investing Stocks and Investing
Wed, June 8, 2011

CATALYST PHARMACEUTICAL PART (NASDAQ:CPRX), Up By 29.87% ($0.41) After BUYINS.NET SqueezeTrigger Report Released on Friday, Jun


Published on 2011-06-08 05:22:36 - WOPRAI
  Print publication without navigation


June 8, 2011 / M2 PRESSWIRE / BUYINS.NET, www.buyins.net , a leading provider of Regulation SHO compliance monitoring, short sale trading statistics and market integrity surveillance, released a report on Friday, June 3rd 2011 at 13:16:00 PDT stating that CATALYST PHARMACEUTICAL PART (NASDAQ:CPRX) was expected to be Up After it crossed above its SqueezeTrigger Price of 1.39 on Friday, June 3rd 2011. Click here to view the BUYINS.NET report: http://www.buyins.net/releases/?sym=cprx&id=170495

From August 2009 to May 2011, an aggregate amount of 22665198 shares of CPRX have been shorted for a total dollar value of $22665198. The CPRX SqueezeTrigger price of $1.39 is the volume weighted average price that all shorts are short in shares of CPRX. There is still approximately $39,640 of potential short covering in shares of CPRX.

SqueezeTrigger.com has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger Price for each stock that has been shorted. The data has then been integrated into an automated trading platform which can be used to connect to a live online broker and automate your trading of short squeeze events. It is extremely powerful with lightening fast execution at a very low price. Both the trading software and SqueezeTrigger data feed are available at http://www.squeezetrigger.com .

CATALYST PHARMACEUTICAL PART (NASDAQ:CPRX) - Catalyst Pharmaceutical Partners, Inc., a development-stage biopharmaceutical company, focuses on the development and commercialization of prescription drugs targeting diseases of the central nervous system with a focus on the treatment of drug addiction and epilepsy. It is evaluating its lead product candidate, CPP-109, a GABA aminotransferase inhibitor, which is under Phase II(b) clinical trial for the treatment of cocaine addiction, as well as focuses on evaluating CPP-109 for the treatment of other addictions and obsessive-compulsive disorders. The company is also developing CPP-115, a GABA aminotransferase inhibitor for various indications, including epilepsy and drug addiction. It has license agreements with Brookhaven Science Associates, LLC on various patents and patent applications relating to the use of vigabatrin as a treatment for cocaine and other addictions, and obsessive-compulsive disorders; and with Northwestern University to commercialize GABA aminotransferase inhibitors worldwide. Catalyst Pharmaceutical Partners, Inc. was founded in 2002 and is based in Coral Gables, Florida.

The SqueezeTrigger database of approximately 1 billion short sale transactions goes back to January 1, 2005 and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005 because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like SqueezeTrigger.com to access the data. Total Short Interest is the number of shares shorted but not yet covered, and is different from total short volume. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.squeezetrigger.com

About BUYINS.NET

BUYINS.NET, http://www.buyins.net, monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market-maker surveillance system tracking market makers in all stocks to determine Price Friction and compliance with new "Fair Market-Making Requirements".

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and all Threshold Security Lists daily for which stocks have naked short positions.

INVESTMENTS & TRADING

SqueezeTrigger -- 28 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts next move in stocks.

GATS -- tracks and quantifies known trading strategies.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. [symbol] has not approved the statements made in this release. Please read our report and visit our web site, http://www.buyins.net, for complete risks and disclosures.

Contact: BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net http://www.buyins.net

Contributing Sources